PharmacyCodes



Teniposidum [Inn-Latin] en es it fr

Teniposidum [Inn-Latin] Brand names, Teniposidum [Inn-Latin] Analogs

Teniposidum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Teniposidum [Inn-Latin] Chemical_Formula

C32H32O13S

Teniposidum [Inn-Latin] RX_link

http://www.rxlist.com/cgi/generic2/teniposide.htm

Teniposidum [Inn-Latin] fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=110

Teniposidum [Inn-Latin] msds (material safety sheet)

Teniposidum [Inn-Latin] Synthesis Reference

No information avaliable

Teniposidum [Inn-Latin] Molecular Weight

656.655 g/mol

Teniposidum [Inn-Latin] Melting Point

No information avaliable

Teniposidum [Inn-Latin] H2O Solubility

No information avaliable

Teniposidum [Inn-Latin] State

Solid

Teniposidum [Inn-Latin] LogP

1.963

Teniposidum [Inn-Latin] Dosage Forms

Liquid

Teniposidum [Inn-Latin] Indication

Treatment of refractory acute lymphoblastic leukaemia

Teniposidum [Inn-Latin] Pharmacology

Teniposide is a phase-specific cytotoxic drug, acting in the late S or early G 2 phase of the cell cycle, thus preventing cells from entering mitosis. Teniposide causes dose-dependent single- and double-stranded breaks in DNA and DNA: protein cross-links. The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA.

Teniposidum [Inn-Latin] Absorption

No information avaliable

Teniposidum [Inn-Latin] side effects and Toxicity

No information avaliable

Teniposidum [Inn-Latin] Patient Information

No information avaliable

Teniposidum [Inn-Latin] Organisms Affected

Humans and other mammals